APBio
圓祥生技股份有限公司
APBio is a Taiwan TPEx-listed biotechnology company; its most advanced asset is IBI302 (Phase 3 primary endpoint met, Wet age-related macular degeneration), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| IBI302 | — | Phase 3 primary endpoint met | Wet age-related macular degeneration | China | 2026-03-24 | Company disclosure |
| AP203 | — | Phase 1 / Phase 2; recruiting | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamous Cell Carcinoma (HNSCC); Esophageal Squamous Cell Carcinoma (ESCC) | Taiwan | 2025-03-26 | Trial registry |
| AP505 / B1962 | PD-L1 x VEGF | Phase 2 | Colorectal cancer; non-small-cell lung cancer | — | — | Company disclosure |
Key events
- AP505 cooperation addendum signed with Tasly (company disclosure)
- IBI302 pivotal Phase 3 STAR study met its primary endpoint (company disclosure)
- AP601 Phase 1 first participant enrolled in Australia (company disclosure)